Journal
NPJ PRIMARY CARE RESPIRATORY MEDICINE
Volume 32, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41533-022-00300-z
Keywords
-
Categories
Funding
- GSK
Ask authors/readers for more resources
This narrative literature review examined the relationship between NSAID use and COVID-19 outcomes. The findings indicate that NSAIDs do not increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. Current recommendations from major public health authorities support the use of NSAIDs for pain relief and fever reduction during the pandemic.
Early in the COVID-19 pandemic, anecdotal reports emerged suggesting non-steroidal anti-inflammatory drugs (NSAIDs) may increase susceptibility to infection and adversely impact clinical outcomes. This narrative literature review (March 2020-July 2021) attempted to clarify the relationship between NSAID use and COVID-19 outcomes related to disease susceptibility or severity. Twenty-four relevant publications (covering 25 studies) reporting original research data were identified; all were observational cohort studies, and eight were described as retrospective. Overall, these studies are consistent in showing that NSAIDs neither increase the likelihood of SARS-CoV-2 infection nor worsen outcomes in patients with COVID-19. This is reflected in current recommendations from major public health authorities across the world, which support NSAID use for analgesic or antipyretic treatment during COVID-19. Thus, there is no basis on which to restrict or prohibit use of these drugs by consumers or patients to manage their health conditions and symptoms during the pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available